Feliza Mirasol

Biologic drug development requires relevant bioassays to measure and help predict cellular response.

Deeper biological understanding and technology innovations have improved the fate of ADC development.

Learning from early market failures, the biopharma industry has worked to improve the fate of antibody drug conjugates.

Using a predictive modeling approach can help tighten up operator control over bioprocessing, which in turn can increase bioreactor output.

The industry revisits the pros and cons of microbial fermentation at scale for biotherapeutics.

A simplified downstream process can save time and costs but requires enabling technologies.

The growth of the biopharmaceuticals market is feeding back into economies and, in part, is driving the boom in life sciences and biotech ecosystems.

An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.

The projected growth in the biosimilars market will require increased bulk mAb manufacturing.

A predictive modeling approach can offer tighter process control, which can optimize bioreactor output.